Join the Class Action Against Capricor Therapeutics Now

Opportunities for Shareholders of Capricor Therapeutics, Inc.

The Gross Law Firm has an important announcement for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). This notice aims to inform you about your rights regarding potential class action claims tied to recent developments in the company's activities related to their drug candidate, deramiocel.

Class Period and Key Dates

If you purchased shares of CAPR between the class period of October 9, 2024, and July 10, 2025, it is crucial to pay attention to these developments. The deadline to register for participation in this class action is approaching on September 15, 2025. It is advisable for shareholders to connect with the Gross Law Firm without delay to explore their options.

Reasons to Join the Class Action

The allegations surrounding Capricor highlight the concerns that investors faced. The complaint suggests that the company provided misleading information about its lead therapy candidate for cardiomyopathy, which is closely tied to Duchenne muscular dystrophy (DMD). The company claimed they were on track to secure a Biologics License Application (BLA) approval from the U.S. Food and Drug Administration (FDA), which proved to be overly optimistic.

Consequences of Recent Developments

On July 11, 2025, Capricor released a significant update, revealing they received a Complete Response Letter (CRL) from the FDA. This letter stated that Capricor had not met the necessary requirements for showing substantial evidence of effectiveness for its drug. As a result, the stock plummeted from $11.40 per share to $7.64 in just one day, reflecting the market's reaction to this unfortunate news.

Act Now: Register and Protect Your Rights

It is vital for shareholders to register their information promptly to safeguard their rights before the impending deadline. Registering does not obligate you to participate as a lead plaintiff, as recovery options are available without this designation. The Gross Law Firm offers a user-friendly platform to facilitate your registration process and monitor the case's progress accurately.

Why Choose the Gross Law Firm?

The Gross Law Firm stands out nationally due to its commitment to protecting investor rights. This firm has a proven track record of advocating for investors who have suffered from fraud and mismanagement. Their mission is to hold companies accountable for any misleading statements or omissions that negatively impact stock prices and investor trust. By joining this class action, you are not merely an observer; you become a part of a movement to demand transparency and integrity in corporate practices.

Get in Touch

If you have further questions or wish to discuss your options, do not hesitate to reach out to the Gross Law Firm:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (646) 453-8903

Frequently Asked Questions

What is the purpose of this class action against Capricor Therapeutics?

The class action aims to address allegations of misleading information that negatively affected investors' decisions and caused stock price drops.

How do I know if I qualify to join the class action?

If you purchased shares of CAPR within the specified class period, you are encouraged to register for participation.

What are the potential outcomes of this class action?

Participants may receive financial compensation if the court rules in favor of the class action, helping to recover losses incurred due to misleading statements.

Is there a cost to join the class action?

No, there are no costs to register or participate in the case. Your participation does not come with any obligations.

How can I follow the progress of the case?

Once registered, you will receive updates and reports throughout the case via the Gross Law Firm, keeping you informed of any significant developments.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.